Identifier
Created
Classification
Origin
05BRASILIA1133
2005-04-28 14:21:00
UNCLASSIFIED
Embassy Brasilia
Cable title:  

APPROVAL OF NIH RESEARCH PROJECT ENTITLED

Tags:  TBIO KSCA OSCI BR 
pdf how-to read a cable
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS BRASILIA 001133 

SIPDIS

STATE PASS TO FDA/INTL PROGRAMS FOR ASSOCIATE DIRECTOR FOR
THE AMERICAS DESK CHARLES GAYLORD

E.O. 12958: N/A
TAGS: TBIO KSCA OSCI BR
SUBJECT: APPROVAL OF NIH RESEARCH PROJECT ENTITLED
"ASSESSMENT OF IDURONATE-2-SULFATASE IN MPS II (HUNTER
SYNDROME) (AIM) PIVOTAL TRIAL" WITH RECOMMENDATION

REF: (A) 04 BRASILIA 01922, (B) 04 STATE 164536

UNCLAS BRASILIA 001133

SIPDIS

STATE PASS TO FDA/INTL PROGRAMS FOR ASSOCIATE DIRECTOR FOR
THE AMERICAS DESK CHARLES GAYLORD

E.O. 12958: N/A
TAGS: TBIO KSCA OSCI BR
SUBJECT: APPROVAL OF NIH RESEARCH PROJECT ENTITLED
"ASSESSMENT OF IDURONATE-2-SULFATASE IN MPS II (HUNTER
SYNDROME) (AIM) PIVOTAL TRIAL" WITH RECOMMENDATION

REF: (A) 04 BRASILIA 01922, (B) 04 STATE 164536


1. On April 18, 2005, Embassy received from the Brazilian
Ministry of Foreign Affairs, Division of Science and
Technology, (DCTEC/MFA) an official notification (number 152,
dated April 15, 2005) approving the research project proposal
entitled "ASSESSMENT OF IDURONATE-2-SULFATASE IN MPS II
(HUNTER SYNDROME) (AIM) PIVOTAL TRIAL," (number RFA-FDA-OPD-
2004-1),under the direction of Dr. Roberto Giugliani, of
Hospital das Clinicas de Porto Alegre, Rio Grande do Sul. An
informal translation of the approval notice follows:


2. Begin text:

Dear Ms. Norman,

I hereby inform you that the Brazilian government has
reviewed the project entitled "Assessment of Iduronate-2-
Sulfatase in MPS II (Hunter syndrome) (AIM) Pivotal Trial" to
be developed by Dr. Roberto Giugliani from Hospital das
Clinicas de Porto Alegre, UFRGS, with financial support from
the Food and Drug Administration (FDA).

2) The aforesaid protocol was approved with a recommendation.
Please see National Commission on Ethics in Research (CONEP)
considerations below:

a)"requests in referred opinion have been duly complied with.
However, it is recommended that:

1 - the sentence "or until sponsor decides to discontinue the
study" in subclause "Continued Protein Supply" be removed.

2 - researchers file a report with CEP assessing
advantages/needs for continued drug use.

b) the project generally meets the basic requirements in
Resolutions CNS 196/96 and 292/99 on Guidelines and
Regulations for Research Involving Human Beings;

c) the project was approved by the Committee of Ethics in
Research (CEP) of the aforementioned institution.
In consideration of the above information, CONEP, drawing its
authority from Resolution CNS 196/96, declares its approval
of the proposed research project which will also include CEP
monitoring of recommendations set forth in a) above."

3) The Ministry of Science and Technology (MCT) has reviewed
and approved the above mentioned protocol, but has reminded
Brazilian researchers that under the legislation in force
they must request the required authorization from the Council
for Scientific and Technological Development (CNPq) prior to
shipping collected data and/or biological material to foreign
countries.

Yours truly,

Vergniaud Elyseu Filho
(Signature)
Head of the Division of Science and Technology
Ministry of Foreign Affairs

End text of translation.


3. The Embassy sees no adverse foreign policy implications
with respect to this research project. We reiterate the
importance of complying with Brazilian law on the export of
data and biological material and medical research involving
human beings.


4. Embassy Science and Health Counselor Patricia Norman would
like to establish contact with the International Officer at
FDA responsible for this grant. Please send email to
normanpd@state.gov
DANILOVICH